

Total Synthesis of Vancomycin Aglycon Boger's Group

**2021.11.20. Literature Seminar
M2 Yuto Hikone**

Contents



0. Introduction

**1. First-Generation Synthesis of
Vancomycin Aglycon
(Dale L. Boger, 1999)**

**2. Next-Generation Synthesis of
Vancomycin Aglycon
(Dale L. Boger, 2020)**

* Reagent structures are listed in page 35.

Vancomycin



Isolation¹⁾

- Domain: Bacteria
Genus: *Amycolatopsis orientalis*
(1950s at Eli Lilly and Company)

Biological activity

- gram-positive organisms
ex). penicillin-resistant staphylococci

Clinical use

- from 1958

Full Structure assignment²⁾

- Harris, C. M and Harris, T. M. (1982)

Structural features

- heptapeptide composed of unnatural amino acid units
- biaryl linkage (AB) -> axial chirality
- bisaryl ether linkage (C-O-D and D-O-E)
-> planar chirality

Total synthesis

Evans (1998)³⁾

Nicolaou (1998)⁴⁾

Boger (1999, 2020)^{5,6)}

1) Levine, D. Vancomycin: a history. Clin. Infect. Dis. 2006, 42, S5–S122).

2) Harris, C. M.; Harris, T. M. J. Am. Chem. Soc. 1982, 104, 4293–4295.


3) Evans, D. A. et al. Angew. Chem., Int. Ed. 1998, 37, 2700–2704.

4) Nicolaou, K. C. Angew. Chem., Int. Ed. 1999, 38, 240–244.


5) Boger, D. L. et al. J. Am. Chem. Soc. 1999, 121, 10004–10011.

6) Boger, D. L. J. Am. Chem. Soc. 2020, 142, 16039–16050


Proposed Biosynthesis



Evans' Total Synthesis (1998)



Nicolaou's Total Synthesis (1998)



1) Nicolaou, K. C. et al. *Angew. Chem., Int. Ed.* **1998**, *37*, 2717–2719.

2) Nicolaou, K. C. et al. *Angew. Chem., Int. Ed.* **1999**, *38*, 240–244.

3) Nicolaou, K. C. Et al. *Chem. - Eur. J.* **1999**, *5*, 2584–2601.

Contents

0. Introduction

**1. First-Generation Synthesis of
Vancomycin Aglycon
(Dale L. Boger, 1999)**

**2. Next-Generation Synthesis of
Vancomycin Aglycon
(Dale L. Boger, 2020)**

Prof. Dale L. Boger




Career:

-1975 : B.S. @ University of Kansas
-1980 : Ph.D. @ Harvard University (Prof. E. J. Corey)
**1979-1985 : Assistant/Associate professor of Medicinal Chemistry
@ University of Kansas**
1985-1991 : Associate Professor/Professor of Chemistry @ Purdue University
1991-1993 : Associate Professor. @University of Illinois at Urbana-Champaign
1991- : Professor. @ The Scripps Research Institute

Research interests:

1. synthetic methodology development
2. natural product total synthesis
3. study of DNA-agent interactions


Model Study for Thermal Atropisomerism (1)




1) Boger, D. L.; Borzilleri, R. M.; Nukui, S.; Beresis, R. T. *J. Org. Chem.* **1997**, *62*, 4721–4736.

2) Boger, D. L.; Castle, S. L.; Miyazaki, S.; Wu, J. H.; Beresis, R. T.; Loiseleur, O. *J. Org. Chem.* **1999**, *64*, 70–80.

Model Study for Thermal Atropisomerism (2)



Synthetic Plan (First-Generation, 1999)



Thermodynamic parameters of atropisomerism (model study)


C-O-D macrocycle (30.4 kcal/mol) > **AB biaryl** (25.1 kcal/mol) > **D-O-E macrocycle** (18.7 kcal/mol)

based on these studies


Rational order of Ring system construction

C-O-D macrocycle → **AB biaryl** → **AB macrolactam** → **D-O-E macrocycle**
→ vancomycin (aglycon)


C-O-D Macrocycle Synthesis





AB Biaryl Synthesis




1. Raney-Ni (100% reduction of NO_2)
 2. HBF_4 , $t\text{-BuONO}$, $\text{MeCN}, 0^\circ\text{C}$, diazotization
 3. $\text{Cu}^{\text{I}}\text{Cl}$ (20 eq.), $\text{Cu}^{\text{II}}\text{Cl}_2$ (60 eq.), $\text{H}_2\text{O}, 0$ to 25°C , 87% (2 steps)
Sandmeyer substitution




$\text{Pd}^0(\text{dba})_3$ (30 mol%)
 $(o\text{-tolyl})_3\text{P}$ (1.5 eq)
 toluene/MeOH/
 1M aqueous Na_2CO_3
 (10/3/1)
 $80^\circ\text{C}, 15 \text{ min}$
 88% (n:un = 1:1.3)
Suzuki biaryl coupling




AB Macrolactamization



D-O-E Macrocyclic Synthesis




Role of Nitrile in the Thermal Atropisomerism




Installation of nitrile, which is dehydrated form of carboxyamide, has an important role in the thermal atropisomerism.

-
- 1) Sheldrick, G. M.; Jones, P. G.; Kennard, O.; Williams, D. H.; Smith, G. A. *Nature* **1978**, 271, 223–225.
 - 2) Boger, D. L.; Miyazaki, S.; Loiseleur, O.; Beresis, R. T.; Castle, S. L.; Wu, J. H.; Jin, Q. *J. Am. Chem. Soc.* **1998**, 120, 8920–8926.


Deprotection of C-Terminus MEM Ether



First-Generation Synthesis



Short Summary



Earlier introduction of more rigid modular
(C-O-D macrocycle → AB biaryl (→ AB macrolactam) → D-O-E macrocycle)
 based on the model studies of thermal atropisomerism



Successful control of thermal atropisomerism
 without affecting other modules already installed

- 1) Boger, D. L.; Miyazaki, S.; Kim, S. H.; Wu, J. H.; Castle, S. L.; Loiseleur, O.; Jin, Q. *J. Am. Chem. Soc.* **1999**, 121, 10004–10011.
- 2) Boger, D. L.; Miyazaki, S.; Kim, S. H.; Wu, J. H.; Loiseleur, O.; Castle, S. L. *J. Am. Chem. Soc.* **1999**, 121, 3226–3227.

Contents

0. Introduction

**1. First-Generation Synthesis of
Vancomycin Aglycon
(Dale L. Boger, 1999)**


**2. Next-Generation Synthesis of
Vancomycin Aglycon
(Dale L. Boger, 2020)**

New Strategy


Remained problems

- Unsatisfactory kinetic atroposelectivities
C-O-D macrocycle (n:un = 1:1), AB biaryl (n:un = 1:1.3)
vs D-O-E macrocycle (n:un = 8:1)
- Inefficiency in recycling of the unnatural atropisomer with thermal isomerism
C-O-D macrocycle (n:un = 1:1.1), AB biaryl (n:un = 3:1)


New Synthetic Strategy





cf. Evans' C-O-D macrocyclization




Atroposelective AB Biaryl Coupling (1)



$\text{Pd}^0_2\text{dba}_3/(R)\text{-BINAP}$ was **ineffective** in this biaryl coupling → Pd^0 -ligated **(R)-BINAP(O)** was the active species




Atroposelective AB Biaryl Coupling (2)




- 1) Moore, M. J.; Qu, S.; Tan, C.; Cai, Y.; Mogi, Y.; Jamin Keith, D.; Boger, D. L. *J. Am. Chem. Soc.* **2020**, *142*, 16039–16050.
 - 2) Marshall, W. J.; Grushin, V. V. *Organometallics* **2003**, *22*, 555–562.

AB Macrolactamization




C-O-D Macrocyclization




Effect of Preorganized AB Macrolactam


C-O-D Macrocyclization before AB macrolactamization




C-O-D Macrocyclization after AB macrolactamization



D-O-E Macrocyclization




Formal Synthesis of Vancomycin Aglycon



Further Improvement


Improved points




vancomycin aglycon	overall yield	kinetic atropselectivity		
		AB	C-O-D	D-O-E
1999 (first)	0.2% (25 steps)	1:1	1:1	8:1
2020 (formal)	0.7% (26 steps)	20:1	7:1	11:1

Remained problems

1. Protecting group manipulations of A-ring amine




2. Competitive reduction in Sandmeyer reaction




3. Early introduction of C-terminus ester

Improvement


- Optimization of Sandmyer reaction




- AB macrolactonization




AB Biaryl coupling/Macrolactamization




C-O-D Macrocyclization



Next-Generation Synthesis



Summary
















Rational order of Ring system construction
enabled by catalyst and substrate control

Sophisticated substrate design
(functional groups and protecting groups)

Kinetical introduction of all atropisomerism
with high diastereoselectivities
(AB > 20:1, C-O-D = 8:1, D-O-E = 14:1)

Improvement in both
synthetic steps and overall yield
(17 steps in 5% vs 25 steps in 0.2%)

Reagent List



Appendix

X-ray Structure of $[(R)\text{-BINAP(O)-}\kappa^2\text{P,O)}\text{Pd-(Ph)I}]$

